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The COVID-19 pandemic poses a barrier to equal and evidence-based management 
of cancer in older adults. The International Society of Geriatric Oncology (SIOG) 
formed a panel of experts to develop consensus recommendations on the 
implications of the pandemic on several aspects of cancer care in this age group 
including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, 
palliative care and research. 
 
Age and cancer diagnosis are significant predictors of adverse outcomes of the 
COVID-19 infection. In this setting, GA is particularly valuable to drive decision-
making. GA may aid estimating physiologic reserve and adaptive capability, 
assessing risk-benefits of either providing or temporarily withholding treatments, and 
determining patient preferences to help inform treatment decisions. In a resource-
constrained setting, geriatric screening tools may be administered remotely to 
identify patients requiring comprehensive GA. Tele-health is also crucial to ensure 
adequate continuity of care and minimize the risk of infection exposure. 
 
In general, therapeutic decisions should favor the most effective and least invasive 
approach with the lowest risk of adverse outcomes. In selected cases, this might 
require deferring or omitting surgery, radiotherapy or systemic treatments especially 
where benefits are marginal and alternative safe therapeutic options are available. 
 
Ongoing research is necessary to expand knowledge of the management of cancer 
in older adults. However, the pandemic presents a significant barrier and efforts 
should be made to ensure equitable access to clinical trials and prospective data 
collection to elucidate the outcomes of COVID-19 in this population. 
 
















The COVID-19 pandemic requires the implementation of individualized approaches 
for the management of cancer in older adults. As of June 2020, there were more 
than 10 million cases and over 500,000 deaths worldwide.[1, 2] The actual 
cumulative death toll from COVID-19 is expected to be higher as reporting varies 
within each country. While the virus affects people of all ages, data have consistently 
shown that mortality is higher with increasing age and comorbidities.[3-6] The case 
fatality rates (CFR) in patients aged less than 70 years were reported as 0.3-3.5%.[7, 
8] This is in contrast to the CFR of  8% in patients aged 70-79 years and around 
15% in those aged over 80 years in China.[7] In Italy, epidemiological data shows 
that the mean age of patients dying from COVID-19 was 80 years,[9] with CFR rising 
with increasing age beyond 70 years: 12.5% (70-79), 19.7% (80-89) and 22.7% 
(over 90).[8] In the United States, the death rate in New York City among patients 
aged 75 years or older was more than 1,511 per 100,000 population[10]. 
 
COVID-19 represents an additional competing risk factor to consider when 
undertaking therapeutic decisions for older adults with cancer (Figure 1). The 
International Society for Geriatric Oncology (SIOG) advocates for  intergrating 
geriatric assessment (GA) to drive decision-making in the management of older 
adults with cancer, especially during the COVID-19 pandemic. . 
 
 Older age and comorbidities such as cardiovascular disease, diabetes, chronic 
respiratory disease, chronic renal impairment, and cancer have been shown to 
increase risk for worse outcomes from COVID-19. [11, 12] In many older patients 
with cancer where management could be challenging, the risks of morbidity and 
mortality from acquiring COVID-19 must be considered when assessing risks and 
benefits of the decision to treat. Currently, personalized care should be the norm in 
treating older patients with cancer; with COVID-19, it becomes even more imperative 
that such an approach is followed to avoid the risk of over- or under-treatment [13] 
and minimize the risk of adopting an ageist approach.  
 
In order to mitigate the negative impact of COVID-19 on the management of cancer 












members from different continents and with different specialties (surgery, radiation 
oncology, medical/geriatric oncology, geriatrics, hematology, nursing, pharmacy) to 
develop recommendations and an action plan based on expert opinion and evidence 
related to geriatric oncology and applied to these circumstances. 
 
 
Impact of the COVID-19 pandemic on older adults with cancer 
 
Cancer is a disease of older adults. On the other hand, baseline information from 
epidemiological data on specific cancer types, stage, and treatment at the time of 
COVID-19 infection are lacking. In the recently published COVID-19 and Cancer 
Consortium (CCC19) cohort, the median age of patients with cancer and COVID-19 
was 66 years, and 56% were aged 65 years and older.[14] Mortality was found to be 
closely associated with age, with patients aged 65-74 and over 75 years having a 
relative risk of death of 11% and 25% respectively, compared to 6% for patients 
below the age of 65 years. In the TERAVOLT cohort of patients with thoracic 
malignancies and COVID-19, age was also closely associated with increased risk of 
death, with patients aged 65 years and older (OR 1.88, 95% CI 1.0-3.6).[15] 
 
In general, COVID-19 is acquired by transmission of a respiratory virus via close 
contact, droplet spray or aerosol, with the duration of viral stability and viability 
maintained depending on various objects or surfaces.[16] Most local and national 
health organizations worldwide have implemented various means to mitigate viral 
transmission and allocate resources appropriately. Primary and secondary 
prevention measures have included home confinement and social distancing of 
patients with cancer, limiting their hospital visits where the risk of acquiring COVID-
19 is high, and reducing iatrogenic immunosuppression and treatment-related 
toxicities, which often leads to inpatient admissions that could put pressure on 
already stretched resources.[17] Goals of care should be established early and 
documented clearly. These should be revisited periodically and must also include 
individualised discussions on advance care planning that should be based on the 













Several geriatric-focused issues have been identified as a result of imposed 
quarantine and social distancing, including: 1) feelings of estrangement and neglect 
due to limited access to news or information, friends and family, particularly when 
access to digital technology is lacking; 2) decline in communication and 
comprehension not only due to isolation but also from wearing masks and face 
shields, more particularly so for hard-of-hearing patients who rely on lip reading and 
non-verbal cues; 3) loss of autonomy and ensuing dependency on others to provide 
basic needs such as medicines, food and other home supplies due to travel 
restrictions or lack of access to transportation; 4) disruption of established 
community support for seniors such as cleaning, shopping, and home maintenance 
to aid them to cope with daily life; 5) increased risk of deconditioning in the outpatient 
setting and following acute medical admissions. In addition, social restrictions and 
shielding can lead to significant decrease in physical activity which, in turn, can 
contribute to or accelerate loss of muscle  mass and bone density, as well as 
mobility and functional impairment in older adults; [18, 19] and 6) institutionalized 
patients, such as those in a nursing care facility are at higher risk of acquiring 




The risk of delirium is especially important and underestimated, called by some 
experts the “silent epidemic within the pandemic.”[22, 23] Leading authorities on 
delirium have found that altered mental status may be one of the first signs of 
COVID-19 infection among vulnerable older adults, and that the current state of 
hospitals and other healthcare settings is becoming more “deliriogenic” as they 
restrict visitors, require all staff members to wear personal protective equipment 
(PPE), and minimize patient interaction to avoid exposure.[24] In these times, it is 
paramount to evaluate in the out-patient setting and stratify the risk of delirium in 
patients prior to administering any anticancer therapy. Hence, the impact of social 
isolation as a result of recommendations on physical distancing, risk of delirium, and 
















Older patients with underlying comorbidities have increased disease severity and 
mortality from COVID-19.[26] Chronological age alone should not drive decisions on 
whether or not to provide life-saving treatments during the pandemic,[27] and yet, 
older patients with cancer are likely to be doubly disadvantaged as health systems 
are overwhelmed.  
 
Prior to this pandemic, frailty had been increasingly adopted as a superior predictor 
of adverse outcomes over chronologic age for older adults in multiple clinical 
settings. In the oncology setting, frailty has been proven to predict toxicity from 
treatment and mortality, and leading cancer societies have recommended GA to 
gauge frailty prior to treatment in older adults to assess such risks.[28-30] The 
decision to treat older patients with cancer is best guided with GA and discussed in a 
multidisciplinary setting to help care providers determine the best treatment options, 
predict treatment-related toxicities, and establish ongoing management for cancer 
and other competing risks.[31] GA is particularly valuable in a context where 
competing risks are more prevalent. GA may estimate physiologic reserve and 
adaptive capability, assess risk-benefits of either providing or temporarily withholding 
treatments, and determine patient preference to help inform treatment decisions. 
 
Different tools, such as the Clinical Frailty Scale and the Frailty Index have been 
proposed to screen and stratify frailty in the setting of COVID-19.[32, 33] However, 
others have highlighted that their use has not been validated in these circumstances, 
and advocate for cautious implementation in the context of the pandemic as clear 
evidence is limited.[34, 35] Additional concerns about the widespread use of these 
tools include the need for standardized training to ensure accuracy in the 
assessment as well as a clear understanding of limitations and appropriateness of 
using these tools to inform, and not replace personalized discussions and care 
recommendations for older adults. In the majority of cases, in the interest of time to 
limit visits and infection exposure for professionals and patients, geriatric screening 
may be sufficient to identify the risk of frailty in some way. The selection of patients 













We recommend using screening tools that can be self-administered by patients, 
such as the G8 screening tool or Vulnerable Elders-13 Survey (VES13).[36] Once 
patients are identified as high-risk for frailty, we recommend further assessment by 
clinicians with geriatric expertise via telemedicine for assessment of function, 
cognitive reserve, mood and delirium, nutritional status, and social support using 
validated tools. 
 
Telehealth has been implemented widely across settings in the midst of the current 
pandemic, and has been shown to be an effective modality [37] even for vulnerable 
populations.[38] Oncology-specific GA can also be conducted via telemedicine. One 
example was outlined by the University of Rochester Specialized Oncology Care and 
Research in the Elderly (SOCARE) and the Ohio State University group. They 
presented a framework for multi-domain GA that can be conducted mostly by 
telephone. This telemedicine version of the GA includes a pre-visit phone screen to 
identify areas of vulnerability and help guide decision-making for older adults with 
cancer (Table 1.[39] 
 
More research on conducting GA in a time-efficient manner is needed and decision-
making should incorporate patients’ preferences and goals, especially in these times 
of heightened risk and uncertainty. Paired with the information derived from a GA, 
goal-concordant care is paramount in partnership with patients and caregivers in 
weighing the risks of COVID-19 exposure and anticancer treatments against the 





Decision-making should be individualized and take into account the potential risk of 
pursuing, delaying or omitting surgery or choosing different surgical approaches. 
(Table 2). For example, open and endoscopic techniques have different intensive 
care requirements, whereas some operations may avoid or delay the need of 
alternative treatments (e.g., neoadjuvant chemotherapy) which may be less safe in 
the context of the pandemic. Along with patients’ fitness and comorbidities that may 












tumor, such as its morbidity and mortality and the presence or absence of ongoing 
cancer-related symptoms, and those associated with the planned surgical procedure 
being considered, in order to ensure the most secure and safest approach to achieve 
local disease control. 
 
Elective surgical procedures scheduled at inpatient facilities may be delayed.[40, 41] 
Nonetheless, the definition of “elective” is sometimes debatable. Apart from 
emergency operations, any essential procedures may include those where a delay 
by two or three months can significantly impact on outcomes and/or those where 
surgery is a crucial component of cancer management, such as for breast, colon, 
gastric, pancreatic, liver, bladder, renal, lung and brain tumors.[42, 43] Selected 
procedures aiming for rapid symptomatic relief and minimizing neurological 
complications should also be prioritized. Surgical management of non-invasive 
tumors, such as breast ductal in-situ carcinoma, can also be delayed since they are 
unlikely to impact on survival outcomes in this age group. 
 
The risk of tumor progression with delayed radical surgery should also be balanced 
with the availability of resources. These include the availability of operating theatres 
that may been converted to intensive care units (ICUs), the local ICU and anesthetist 
capacity, the risk of surgical complications, and the expected recovery time.[44] The 
presence of pre-existing lung conditions that can increase the risk of complications 
should also be considered, along with the need to perform aerosol-generating 
procedures. For patients who require surgery, measures should be put in place to 
mitigate risks, such as preoperative testing and isolation, use of PPE and cohorting 
operations in COVID-19-free areas.  
 
An observational study of 1,128 patients undergoing surgery and who had a 
confirmed COVID-19 infection within 7 days before or 30 days after the procedure 
reported more than 2-fold increase in 30-day mortality for those aged 70 and older 
(OR 2.30).[45] Consequently, the most effective surgical procedures with minimal 
invasiveness, least post-operative morbidity, and fastest recovery time should be 













Delaying surgery may be appropriate for selected older patients while monitoring the 
cancer behaviour until the outbreak is under control. For example, a 60-day delay to 
surgery for stage I-II breast cancer patients had no detrimental impact on outcomes 
in a retrospective analysis from a single academic hospital.[46] Less toxic systemic 
treatment such as endocrine therapy or radiotherapy may be considered means to 
delay surgery in selected cases, as discussed below. Nonetheless, predicting when 
the outbreak will end, even at a local level remains a significant challenge. 
 
As surgery gets delayed, prehabilitation may be adopted during pandemic to ensure 
that fitness to treatment is achieved or maintained while waiting, to minimize post-op 
morbidity and mortality, which may include physical exercise, nutritional support, as 
well as management of comorbidities, health risks and psychosocial factors.[47] 
However, such intervention should be implemented in the context of the 
recommended strategies to minimize the risk of COVID-19 transmission.  
 
In certain circumstances, omitting surgery may be appropriate when the impact on 
symptoms and survival is minimal or if a safe and effective alternative systemic 
treatment is available. For example, the use of primary endocrine therapy for older 
patients with early-stage ER-positive, HER2-negative breast cancer is supported by 






Similarly, the use of radiation therapy (RT) in older patients should be prioritized 
based on its intent, expected benefits, and tumor characteristics in the context of 
patients’ fitness and preference (Table 2). In the older age group, social issues, 
traveling constraints, daily hospital visits, and patients’ concerns regarding exposure 
may represent significant challenges requiring careful consideration. 
 
Furthermore, radiation dose, fractionation and techniques should be optimized and 
adapted to the emergency context. In the curative setting, hypofractionated regimens 












neoadjuvant RT should be favored over a more prolonged course of 
chemoradiotherapy for older patients with locally advanced rectal cancer, with the 
aim of minimizing the need for hospital attendance and the chances of 
myelosuppression.[52] For early breast cancer, 15% of patients enrolled in the 
FAST-Forward study experimental arm were aged 70 years and older and this trial 
confirmed non-inferiority of a shorter course of adjuvant RT (26 Gy in 5 fractions) 
compared with a standard regimen of 40 Gy in 15 fractions.[53] Modest 
hypofractionation can also be considered for patients with early prostate cancer.[54] 
Such regimens are appropriate alternatives to minimize the risk of infection exposure 
in older patients. Despite its role still being debated, intraoperative RT may be 
considered to spare older adults undergoing surgery from having subsequent 
outpatient appointments.[55, 56] Specific guidance is available on RT regimens for 
patients with hematological malignancies. [57] 
 
In the palliative setting, patients should be offered the smallest number of fractions to 
minimize the need to attend the hospital and potential exposure to infection. For 
bony pain relief, a single 8 Gy fraction should be favored as equally effective as 
multiple fractions.[58] A single fraction also can be offered  in case of metastatic cord 
compression.[59] The role of whole brain RT for the management of brain 
metastases remains controversial as medical treatments might already be beneficial 
with regard to symptom control.[60] In contrast, stereotactic body RT (SBRT) might 
still be appropriate in the context of its better safety profile, which is particularly 
relevant in frail and older individuals.[61] 
 
RT should be delayed in the absence of any significant impact on cancer 
management outcomes. On the other hand, in cases of curative intent or rapidly 
progressive disease, the risks of delaying RT might outweigh the risks of COVID-19 
exposure and infection.[62] Patients already undergoing RT should be offered a 
discussion about the risks and benefits of continuing it based on individual goals of 
care.[51, 63]  
 
For patients with early-stage breast cancer, RT can be safely delayed for up to five 
months for those receiving chemotherapy followed by endocrine therapy.[64] RT can 












disease while aiming for either active surveillance or upfront androgen deprivation 
therapy (ADT);[65, 66] in cases of high-risk disease, RT can be delayed for up to 2-3 
months while starting patients on ADT.[67] 
 
In the curative setting, survival gains may be modest in older patients in the context 
of competing risks of mortality including COVID-19 and careful consideration should 
be given to balancing risks and benefits. Treatments reducing the risk of locoregional 
recurrence in the absence of any survival improvement may be appropriately 
omitted.[68] For older patients with low-risk disease, breast radiotherapy can be 
safely omitted.[69, 70] Also, adding a RT boost for patients with early-stage breast 
cancer does not improve survival outcomes and might cause additional toxicities in 
older patients. In the palliative setting, RT should be pursued when any other 
options, including medical treatment (such as analgesia and bisphosphonates for 
bone pain), have been exhausted.  
 
Finally, in the context of the pandemic, RT in the form of either SBRT or conventional 
fractionation may represent a reasonable alternative to surgery in selected cases, 
such as older patients with stage I-II non-small cell lung cancer.[71] SBRT may be 
valuable in this setting in view of the limited number of fractions required (usually 1-
5) to spare patients potentially prolonged admission and postoperative 
complications. Combined data from two trials comparing SBRT with surgery showed 
better 3-year overall survival for SBRT and no differences in locoregional and distant 
recurrence, although this analysis should be interpreted with caution in view of the 
small number of patients enrolled.[72] The practicalities of reducing infection risk 
within the radiotherapy department and educating patients on appropriate safety 





The potential benefits of systemic treatments (including chemotherapy, targeted 
therapy, endocrine therapy and immunotherapy) in terms of tumor control are 
unchanged during a pandemic. However, risks may be higher especially for 












increased infection exposure. Nonetheless, the balance of risks and benefits remains 
uncertain as there is no evidence suggesting that changing or withholding systemic 
treatment is beneficial during a pandemic (Table 2).[75] Therefore, decision-making 
should again be individualized based on consideration of tumor biology, type of 
systemic therapy, patients’ general health status and preferences in the context of 
the presence of cancer-related symptoms (in cases of active disease), local 
prevalence of COVID-19, the availability of healthcare system resources, and the 
risk of infection exposure. Guidelines focusing on delivering specific systemic 
treatments during the pandemic are also available.[63] 
 
Models based on GA have been developed to predict chemotherapy toxicity and 
may aid therapeutic decisions in older patients. Therefore, their implementation is 
particularly appropriate in the context of the ongoing COVID-19 pandemic. The 
Cancer and Aging Research Group (CARG) model takes into account age, type of 
cancer, proposed chemotherapy regimen, renal and hematologic function, hearing, 
along with GA domains such as ability to take medications, physical activity and 
social activity.[76, 77] The Chemotherapy Risk Assessment Scale for High age 
(CRASH) is based on the specific chemotherapy regimen being considered as well 
as laboratory values (creatinine, albumin, hemoglobin, lactate dehydrogenase, liver 
function tests) and assessments of functional, mental, and nutritional status.[78] 
 
In the curative setting, chemotherapy should be considered if indicated and in the 
presence of clear survival benefits, which may be less established in the older age 
group.[79] If possible, a shorter treatment duration should also be considered. In the 
palliative setting, shared decision-making should also take into account the hazards 
of worsening symptoms and functional status, which may lead to losing the 
opportunity to treat.[80] Discontinuing chemotherapy may be an option for some 
patients with low volume disease or after attaining ongoing disease, especially if 
alternative non-myelosuppressive agents are available, such as endocrine therapy 
for hormone receptor-positive breast cancer patients. 
 
In general, evidence-based chemotherapy regimens that require less frequent 
dosing should be favored in order to minimize the need for hospital attendance, 












appropriate, oral agents should be considered in place of intravenous treatments, as 
long as there is evidence to support this change. For example, capecitabine can 
substitute for fluorouracil in managing colorectal malignancies without compromising 
outcomes.[81] Whenever possible, physicians should attempt to utilize existing 
evidence to choose strategies shown to be of similar efficacy (in both the younger 
and older population) over more intensive and/or toxic regimens. Relevant examples 
include offering three instead of six months of adjuvant chemotherapy for patients 
with stage III colon cancer,[82] utilizing a 40% dose reduction of combined oxaliplatin 
and capecitabine chemotherapy for frail or older patients with metastatic gastric 
cancer [83], or opting for best supportive care alone over  chemotherapy for 
vulnerable/frail patients with advanced lung cancer.[84]  
 
Primary prophylaxis with granulocyte colony-stimulating factors is advisable for 
patients receiving chemotherapy in view of the higher risk of myelosuppression in 
older individuals.[85-87] Home-drawn blood service can also be considered, along 
with setting up courier drug delivery and home treatment administration systems to 
minimize the need to travel to the hospital. The National Comprehensive Cancer 
Network (NCCN) has issued a toolkit to facilitate the shifting of systemic  anticancer 
treatments for hematologic malignancies from inpatient to outpatient setting.[88] 
 
In older patients with hematological malignancies, the risk of disease and treatment-
related lymphopenia and neutropenia should also be considered and integrated in 
decision-making.[89] Likewise, the need for anti-CD20 monoclonal antibodies should 
be critically evaluated in view of the adverse impact of lymphopenia on COVID-19 
outcomes.[90] Data are limited on the impact of immunotherapy on COVID-19 and 
potential risks and benefits should be balanced and personalized in older patients. 
Nonetheless, the less frequent dosing of some immunotherapy agents is particularly 
attractive in this context to minimize the need for hospital visits.[91] 
 
Systemic treatment given in the adjuvant setting can be delayed within the accepted 
timing for each tumor type. For example, for patients with colorectal or lung cancer, it 
can be safely postponed for up to 8 weeks,[92, 93] and for those with breast cancer 
for up to 12 weeks after surgery.[94] Older patients should not be denied systemic 












should consider individual circumstances that are likely to influence a significant 
impact on survival or symptom control, including life expectancy, comorbidities and 
tumor biology, in the context of patients’ preferences.  
 
Systemic therapies may also be considered as effective means to delay surgery in 
selected cases. A neoadjuvant endocrine approach is particularly valuable for older 
patients with estrogen receptor-positive, human epidermal growth factor receptor 2 
(HER2)-negative breast cancer, as aromatase inhibitors are associated with low 
toxicity and reasonable response rates at 3-4 months.[95] ADT may also be 
considered preoperatively for selected older adults with prostate cancer, although 
evidence on its impact on radical resection rates is still scarce.[96, 97] Despite the 
benefits, the use of upfront chemotherapy, e.g. taxanes, in the pandemic setting is 
more questionable in view of the higher risk of myelosuppression and infections in 
the older age group, the need for more hospital visits and clinician-patient contact, 
not unless the risks are outweighed by the benefits of rapid disease control to allow a 





Despite the scarcity of health resources brought on by the pandemic, attention needs 
to be paid for the provision and maintenance of palliative care services. COVID-19 
restrictions and physical distancing guidelines have resulted in reduced access to 
available information, care and supports from families and friends, as well as social 
and personal care services that allow older persons, including those living with 
disabilities, to cope at home. Older persons with cancer may present with symptoms 
associated with their malignancy or treatment toxicity, exacerbation of comorbidities 
or COVID-19 that may require hospital admission for critical care and/or referral to 
palliative care. 
 
Early discussion of advance care plans should be implemented to determine 
patients’ preferences and treatment goals. Telemedicine can also facilitate 
communication with older adults in home settings and institutions as appropriate. 












support older patients during end of life care in critical and palliative care setting, 
including psycho-social and spiritual support. Infection control procedures should 
apply also to palliative care settings. The demand for palliative care services (at 
home or residential care facilities, in hospitals or  hospices) may increase and this 
should be adapted to respond rapidly and flexibly during the pandemic,[100] within 





Cancer survivors include people who have completed initial treatment with no 
evidence of active disease or those living with progressive disease who may be 
receiving cancer treatment but are not in the terminal phase of illness [101]. Older 
people account for more than two-thirds of cancer survivors [102]. However, COVID-
19 may disproportionately impact older cancer survivors’ physical health and 
psychosocial wellbeing, which may lead to unintended consequences in the long-
term [103]. Despite social and outdoor activities being on hold due to COVID-19 
restrictions, it is recommended to avoid sedentary lifestyle by maintaining physical 
activity by integrating exercise into the daily routine [104].  
 
Delivery of high-quality, tailored, person-centred survivorship care to address the 
unique needs of older cancer survivors during the pandemic is challenging. 
Nonetheless, as evidence here is still lacking, the recommendations valid for the 





The COVID-19 pandemic presents a further major barrier to participation in clinical 
trials for older adults with cancer, who are already under-represented in oncology 
studies.[105] Screening and/or enrolment for certain clinical trials have been either 
halted or prioritized in several research programs worldwide.[106] Nonetheless, 
where feasible, it is imperative to continue facilitating the access of older patients to 












relevant for this age group while complying with current regulations and limiting the 
consequences on study integrity.[107, 108] The US Food and Drug Administration 
and the European Medicines Agency have issued specific recommendations on this 
topic.[109, 110] 
 
In addition, more evidence on the impact of the COVID-19 pandemic in older adults 
with cancer is warranted. With many preventive (i.e. COVID-19 vaccine) trials 
underway, inclusion of eligible older patients with cancer should be considered. As 
recently outlined by the CARG investigators,[25] multicenter and international 
collaborations and novel methods of rapid dissemination will be crucial to elucidate 
the interaction between global health measures (rather than age alone) and 
oncological outcomes, along with endpoints particularly meaningful for older adults, 




Recommendations and action plans 
 
COVID-19 is an emerging and rapidly evolving condition that warrants tailored care 
and assessment depending on the disease prevalence. As society grapples with the 
pandemic and how best to deliver cancer care in older patients, there is an urgent 
need to act now to protect the vulnerable and mitigate the projected negative 
outcomes in this age group. As this is unlikely to be the last pandemic that we will 
encounter, it is imperative to take this unique opportunity to learn and devise 
management plans for both present and future use. It should also be acknowledged 
that the previously mentioned recommendations may lead to different 
implementation depending on the stage of the pandemic. Whilst data are still 
emerging and median follow-up from published trials is short to make robust 
conclusions, the SIOG Working Group has developed a number of recommendations 
on the management of older adults with cancer and future directions, which are 
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Table 1 – The modified telehealth University of Rochester Specialized Oncology Care and Research in the Elderly 
(SOCARE) geriatric assessment [adapted from: DiGiovanni G et al, J Geriatr Oncol, 2020] 
GA domain Modified tele-health SOCARE GA 
Functional status OARS: Instrumental Activities of Daily Living 
1) Can you use the telephone? 
2) Can you get to places out of walking distance? 
3) Can you go shopping for groceries or clothes (assuming you have transportation)? 
4) Can you prepare your own meals? 
5) Can you do your housework? 
6) Can you take your own medicines 
7) Can you handle your own money? 
8) Can you walk about one block? 
Fall history 
1) In the past year, have you fallen down? 
2) About how long ago was your most recent fall? 
Fatigue rating 
1) Do you experience fatigue and weakness? 
2) If yes, rate your fatigue on a scale of 1-10 (10 = severe, 0 = absence). 
Hearing 1) How is your hearing (with a hearing aide, if needed)? 
2) If hearing is fair to totally deaf, how much does it interfere with activities? 











Completed by geriatric oncologist during visit 
Polypharmacy Medication review 
Nurse Navigator confirmed current medications and provided list to SOCARE pharmacist for review and 
potential recommendations 
Nutrition Weight loss 
1) Have you lost weight in the past 6 months (involuntarily)? 
2) What is your weight now? 
3) What was your weight 6 months ago? 
Cognition Blessed Orientation Memory Concentration 
Conducted in person by occupational therapist during visit 
Social support 1) Who do you live with? 
2) Who is your main social support? 
Psychological status PHQ-2 
1) In the last two weeks, how often have you been bothered by(0 =Not at all, 1=Several 
days, 2 = More than half the days, 3 = Nearly every day) 
a) Limited interest/pleasure in doing things? 
b) Feeling down, depressed, or hopeless? 
Abbreviations: GA: geriatric assessment; OARS: Older Americans Resources and Services; MOS: Medical Outcomes Survey; 













Table 2 – Summary of the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group recommendations 
on various domains of cancer care. 
 
Care domains Recommendations 
General 
interventions 
 Maintain physical distancing to reduce risk of exposure and viral transmission 
 Implement strict infection control policies in residential care facilities and hospitals, and minimize or 
discourage all non-essential visits 
 Deploy telehealth care via telephone or video link to protect both the patient and the clinician and 
provide continuity of care despite social containment 
 Encourage digital literacy and provide access to online technologies to maintain social network with 
family, friends, support workers and care providers 
 Implement a coordinated and pragmatic treatment journey to rationalize and/or minimize hospital 
appointments 
 Identify early, periodically re-evaluate and clearly document the goals of care 
 Consider advance care planning discussions where appropriate 
Care domains Recommendations Practical examples 
Geriatric 
assessment 
 Implement remote geriatric screening as a more time- 
and resource-efficient strategy to select older patients 
requiring a more comprehensive assessment 
 Conduct geriatric assessments by implementing 
telehealth via platforms in compliance with local 
 Self-administered screening tools: G8, 
VES-13 
 











electronic health care regulations 
 Adopt a “virtual” geriatric-focused multidisciplinary 
team approach through the use of videoconferencing 
platforms to enable tumor board meetings in 
compliant with local regulations 
Surgery  Prioritize surgical management based on patients’ 
global health status and wishes, setting (curative 
versus palliative), type of surgery and risk of 
complications, need for general or local anesthetics, 
expected recovery time, availability of hospital 
resources, presence of cancer-related symptoms 
 Defer noncritical surgery especially if neoadjuvant 
non-myelosuppressive systemic treatment options are 
available and while ensuring adequate disease 
behavior monitoring 
 Consider omitting surgery in selected cases if no 
clear survival or symptom control benefit especially if 
safe systemic or radiotherapy options are available 
 Use local anesthetics if appropriate 
 Consider neoadjuvant endocrine 
therapy to defer breast cancer surgery 
for HR-positive, HER2-negative breast 
cancer 
 Consider primary endocrine therapy 
instead of surgery for HR-positive, 
HER2-negative breast cancer 
Radiotherapy  Prioritize radiation therapy approaches based on 
patients’ global health status and wishes, setting 
(curative versus palliative), fractionation and dosing, 
 Hypofractionation for breast cancer  
 Short- course neoadjuvant 











risk of side effects, availability of hospital resources, 
presence of cancer-related symptoms 
 Delay noncritical radiotherapy within disease-specific 
safe time intervals in the adjuvant setting especially if 
systemic treatment options are available 
 Omit radiotherapy if no clear survival or symptom 
control benefit 
 Single-fraction radiotherapy for 
palliative purposes 
 Intraoperative radiotherapy for breast 
cancer 
 Stereotactic radiotherapy for early non-
small cell lung cancer or central 
nervous system metastases 
 Consider ADT to delay radiotherapy for 
early prostate cancer 




 Prioritize systemic treatments based on patients’ 
global health status and wishes, setting (curative 
versus palliative), class of agents, expected toxicities, 
availability of hospital resources, presence of cancer-
related symptoms 
 Implement the use of chemotherapy toxicity prediction 
tools 
 Implement home delivery services for oral agents, 
home blood service and home treatment 
administration if available 
 CARG or CRASH chemotherapy 
toxicity prediction tools 
 Neoadjuvant endocrine therapy for 
HR-positive, HER2-negative early 
breast cancer, particularly for those 
with lobular histology or Luminal-A like 
subtype 
 Primary endocrine therapy for HR-












 Prescribe primary G-CSF prophylaxis to limit risk of 
myelosuppression 
 Delay noncritical systemic treatments within disease-
specific safe time intervals in the adjuvant setting 
 Omit systemic therapy if no clear survival or symptom 
control benefit 
 Substitute oral for intravenous 
preparation, i.e. oral vinorelbine for day 
8 treatment; capecitabine for 
fluorouracil for the treatment of GI 
malignancies 
 Consider omitting adjuvant 
chemotherapy for patients with low-risk 
HR-positive, HER2-negative breast 
cancer and in low-risk Stage II 
colorectal cancer 
 Consider 3 over 6 months adjuvant 
treatment for Stage 3 colorectal cancer 
 Omit oxaliplatin in Stage 3 colorectal 
cancer where the benefit in older 
patients is lacking 
 Consider ADT to delay surgery and/or 
radiotherapy for early prostate cancer 
 Preference for a less frequent 
treatment dosing schedule, i.e. 












Palliative Care  Discuss advance care plans to determine care preferences and goals, such as do not attempt 
cardiopulmonary resuscitation orders, endotracheal intubation, or dialysis 
 Use telemedicine and videoconferencing to facilitate communications with older persons in home 
settings and institutions as appropriate and evaluate their efficacy 
 Use palliative care techniques to communicate with families and support older patients dying in critical 
and palliative care settings 
 Provide WHO recommended infection control procedures and other guidance on PPE, as well as 
psycho-social and spiritual support to staff in hospitals, nursing homes, hospices and community 
settings to ensure well-being and resilience 
Survivorship  Avoid sedentary lifestyle by integrating home-based physical exercises into daily routine 
 Either or a combination of 150 minutes of moderate intensity or 75 minutes of vigorous intensity of 
physical activity per week, depending on the pre-existing level of function 
 Schedule short active breaks during the day, which may include standing every hour, walk around the 
block or walk several times inside the house, or follow regimen from online exercise class 
 Practice meditation, mindfulness and deep breathing exercise 
 Integrate cognitively stimulating activities, i.e. puzzles, reading, or board games 
 Monitor nutrition, avoid substance abuse, and control comorbidities by coordinating with the primary 
care provider 
Abbreviations: VES-13: Vulnerable Elders Survey-13; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; 











colony-stimulating factor; ADT: androgen deprivation therapy; SOCARE: University of Rochester Specialized Oncology Care and 
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